A new drug that many hope could revolutionise treatment of a certain
form of heart failure has now been given a green light for use in
Europe.
Novartis’ Entresto (sacubitril/valsartan) has been approved by the
European Commission to treat patients with heart failure and reduced
ejection fraction, a condition where the heart muscle does not contract
effectively and less oxygen-rich blood is pumped out to the body.